Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Von Willebrand Disease

Blood & Immune

Von Willebrand Disease Clinical Trials and Treatments

Also called vWD, von Willebrand factor deficiency, angiohemophilia

Von Willebrand disease (vWD) is the most common inherited bleeding disorder, estimated by MedlinePlus Genetics to affect 1 in 100 to 1 in 10,000 people. It results from quantitative (Type 1: partial deficiency, Type 3: complete absence) or qualitative (Type 2: dysfunctional) deficiency of von Willebrand factor (vWF), a glycoprotein critical for platelet adhesion and carrier of factor VIII.

In plain words, von Willebrand disease is an inherited bleeding condition where a protein that helps blood clot is low or does not work well. People may get nosebleeds and bleeding gums, easy bruising, or long bleeding after injuries.

Get an email when new Von Willebrand Disease trials open or the FDA decides. Get alerts

Von Willebrand Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines3

Vonvendi · DDAVP Injection · Humate-P

Von Willebrand Disease has 3 FDA-approved medicines, 27 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Von Willebrand Disease

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Von Willebrand Disease

Type 1 is autosomal dominant, comprising approximately 75% of cases. Type 3 is autosomal recessive with complete vWF absence and most severe phenotype. Type 2 encompasses multiple dysfunctional variants with variable inheritance patterns. Pathophysiology involves impaired platelet adhesion to damaged endothelium and reduced factor VIII levels.

Keep reading about Von Willebrand Disease

Clinical manifestations include mucosal bleeding (epistaxis, gingival bleeding, GI bleeding), heavy menstrual bleeding (particularly symptomatic in women), and excessive bleeding with trauma or surgery. Bleeding severity varies within the same type and even within affected families. Type 2 variants show markedly variable presentation. Type 3 patients have complete absence of functional vWF and factor VIII deficiency approaching hemophilia severity. Diagnosis requires vWF activity and antigen level measurement, factor VIII activity assay, and bleeding phenotype assessment.

What are the symptoms of Von Willebrand Disease?

These are common symptoms of Von Willebrand Disease, and how strong they are varies from person to person.

  • Easy bruising and mucosal bleeding
  • Heavy menstrual bleeding in women
  • Nosebleeds
  • Gum bleeding
  • Prolonged bleeding after trauma or surgery
  • Gastrointestinal bleeding in severe forms

Who gets Von Willebrand Disease?

Affects males and females equally in Types 1 and 3. Women disproportionately affected by bleeding symptoms due to menstrual blood loss and pregnancy-related complications. All ethnic backgrounds affected with similar prevalence. Type 1 autosomal dominant; Types 2 and 3 variable inheritance with Type 3 autosomal recessive.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Von Willebrand Disease?

There are currently 3 FDA-approved medications for Von Willebrand Disease.

DDAVP Injection
desmopressin acetate
Humate-P
antihemophilic factor/von willebrand factor complex (human)
von willebrand factor (recombinant) (vonicog alfa)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Von Willebrand Disease treatment

Charity funds and drugmaker programs for Von Willebrand Disease, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · Hemophilia Federation of America
    Helping Hands Program fund
    Open

    Pays for: Emergency living expenses ($250 prepaid card, once per year; referral through HTC or member organization; does not cover medical bills, copays or premiums), up to $250 per year.

    The foundation says: “The Helping Hands program is now open on a limited basis for 2026. Due to funding constraints, a maximum of 20 requests will be approved…”
Status as each foundation showed it on November 16, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Von Willebrand Disease, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Von Willebrand Disease

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Von Willebrand Disease resources

Reputable organizations and medical references for learning more about Von Willebrand Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Von Willebrand Disease

Use this Von Willebrand Disease clinical trial finder to see the 20 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 11 test a treatment and 11 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

27 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT06998524

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Intervention: Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents

Sponsor: Hoffmann-La Roche

This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been diagnosed with Type 3 von Willebrand disease (VWD). Partic...

Ages 1 Month+
Started Jun 2025Updated 2 days agoEst. Oct 2027 (~10 months)
RecruitingTreatment trialPhase 2Recently updatedNCT07575308

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Intervention: ALN-6400

Sponsor: Alnylam Pharmaceuticals

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Ages 16 Years to 45 Years
Started Jul 2026Updated 5 days agoEst. Jun 2027 (~7 months)
RecruitingObservational study, no treatment givenRecently updatedNCT05916469

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

Intervention: Levonorgestrel Intrauterine System, Norethindrone Acetate

Sponsor: Oregon Health and Science University

The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months ...

Ages 10 Years to 24 Years
Started Sep 2025Updated 2 weeks agoEst. Dec 2028 (~2y 1m)
RecruitingTreatment trialPhase 3Recently updatedNCT06205095

A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD

Intervention: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII, Placebo

Sponsor: Unity Health Toronto

The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and v...

Ages 18 Years+2 locations
Started Oct 2024Updated 1 month agoEst. Dec 2027 (~1y 1m)
RecruitingTreatment trialPhase 3Recently updatedNCT07115004

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

Intervention: VGA039

Sponsor: Vega Therapeutics, Inc

This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)

Ages 12 Years to 75 Years
Started Oct 2025Updated 2 months agoEst. Oct 2028 (~1y 11m)
Find Von Willebrand Disease trials near you, ranked by distance →
Active trial locations85 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+77 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Von Willebrand Disease trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Von Willebrand Disease foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Von Willebrand Disease patient communities

Facebook groups, Reddit communities and YouTube channels where Von Willebrand Disease patients, caregivers and advocacy groups talk.

Companies developing Von Willebrand Disease treatments

Drugmakers that list Von Willebrand Disease in their rare disease portfolio, 7 in all.

Questions people ask about Von Willebrand Disease